文献速递抗栓抗凝管理药物不良反应与药物警戒

房颤抗凝净效应需治疗人数:真实世界与临床试验证据对比

Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence.
PubMed 文献 · Br J Clin Pharmacol · 2021-07-13

该研究基于真实世界Murcia房颤项目与AMADEUS临床试验的患者数据,采用CARS计算器评估基线卒中风险,计算口服抗凝药净效应需治疗人数(NNTnet)。真实世界队列NNTnet为34,临床试验队列为46;两队列中CARS评估额外卒中风险≥2%的患者NNTnet显著更低。

要点

  • 真实世界队列OAC的NNTnet为34,临床试验队列为46。
  • 真实世界队列ARRstroke为4.0%,ARIbleeding为1.0%。
  • 临床试验队列ARRstroke为3.8%,ARIbleeding为1.6%。

核心结论

  • NNTnet方法整合基线卒中风险、大出血风险及OAC相对效应,可评估房颤抗凝净获益。

研究设计与样本

  • 真实世界Murcia房颤项目与AMADEUS临床试验患者数据的回顾性分析,共纳入3511例患者(真实世界1306例,临床试验2205例)。

主要发现

  • 真实世界队列:OAC相关ARRstroke为4.0%,NNTbenefit为25,ARIbleeding为1.0%,NNTharm为100,NNTnet为34。
  • 临床试验队列:OAC相关ARRstroke为3.8%,NNTbenefit为27,ARIbleeding为1.6%,NNTharm为63,NNTnet为46。
  • 两队列中CARS评估额外卒中风险≥2%的患者NNTnet显著更低。
  • 两队列1年绝对卒中风险相似。

关键数值与推荐

  • NNTnet计算公式为1/(ARRstroke - ARIbleeding)。
  • 基线卒中风险采用CARS计算器评估。
  • 卒中与大出血事件风险基于1年事件数确定。

临床怎么用

  • 临床可参考NNTnet方法综合评估房颤患者抗凝净获益。
  • 对CARS评估额外卒中风险≥2%的患者,抗凝净获益可能更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The net benefit of oral anticoagulants (OACs) in atrial fibrillation (AF) is poorly understood. We aimed to determine the NNT for net effect (NNTnet ) using calculator of absolute stroke risk (CARS) in anticoagulated patients with AF in real-world and clinical trial cohorts. METHODS: Post-hoc analysis of patient-level data from the real-world Murcia AF Project and AMADEUS clinical trial. Baseline risk of stroke was determined using CARS. The risk of stroke and major bleeding events with OAC were determined using the number of respective events at 1-year. NNTnet was calculated as a reciprocal of the net effect of absolute risk reduction with OAC (NNTnet = 1/(absolute risk reduction of stroke[ARRstroke ] - absolute risk increase of major bleeding[ARIbleeding ])). RESULTS: In total, 3511 patients were included (1306 [37.2%] real-world patients and 2205 [62.8%] clinical trial participants). The absolute 1-year stroke risk was similar across both cohorts. In the real-world cohort, OAC was associated with a 4.0% ARRstroke , 25 NNTbenefit , 1.0% ARIbleeding , 100 NNTharm and 34 NNTnet . In the clinical trial cohort, OAC was associated with a 3.8% ARRstroke , 27 NNTbenefit , 1.6% ARIbleeding , 63 NNTharm and 46 NNTnet . In both cohorts, the NNTnet was significantly lower in patients with an excess stroke risk of ≥2% by CARS. CONCLUSION: Overall, the NNTnet approach in AF incorporates information regarding baseline risk of stroke and major bleeding, and relative effects of OAC with the potential to include multiple additional outcomes and weighting of events based on their perceived effects by individual patients.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ding WY, Rivera-Caravaca JM, Marín F, et al. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence. Br J Clin Pharmacol. 2021. PMID: 34192808. doi:10.1111/bcp.14961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。